Common Contracts
2 similar License Agreement contracts by Biotime Inc
ContractLicense Agreement • May 5th, 2020 • California
EX-10.2 3 ex10_2.htm EXHIBIT 10.2 Exhibit 10.2 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. LICENSE AGREEMENT dated August 17, 2017 by and between BioTime, Inc. and AgeX Therapeutics, Inc. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. TABLE OF CONTENTS
LICENSE AGREEMENTLicense Agreement • November 9th, 2017 • Biotime Inc • Biological products, (no disgnostic substances) • California
LICENSE AGREEMENT (this “Agreement”) dated August 17, 2017 (the “Effective Date”) by and between BioTime, Inc,, a corporation incorporated under the laws of the State of California, United States of America (“BioTime”), and AgeX Therapeutics, Inc., a corporation incorporated under the laws of the State of Delaware, United States of America (“AgeX”) (each, a “Party” and, collectively, the “Parties”).
